Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q1 FY22 Earnings Presentation
26 slides from Shilpa Medicare's earnings presentation, Aug 14, 2021
Slide 1: Shilpa Medicare Limited filing cover letter
Shilpa Medicare Limited Corporate & Admin Office: Innovating for "Shilpa House", # 12-6-214/A-1, Hyderabad Road, Iaffordable healthcare Raichur-584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN:L85110KA1987PLC008739 Dated 14 Augu
Slide 2: Q1 FY22 Results Presentation
Shilpa Medicare Limited (SML) Q1 FY22 Results Presentation 1
Slide 3: Disclaimer
2 Disclaimer Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political Jadcherla Unit, Telangana or economic developments, and many other factors that could cause our
Slide 4: Company Overview
Company Overview 3 Pursuing niche growth businesses like Transdermal, Oral Dissolving Films and Dermatological Formulations Established presence in Active Pharmaceutical Ingredients (APIs) and Formulations for Affordable & Robust research domestic & international markets Effective orientation result
Slide 5: Table of Contents
Table of Contents 4 Financial Performance........................................05 Discussion of Select Business Segments................... 09 Other Updates.................................................14 Way Forward……….........................................22
Slide 6: Financial Performance
Financial Performance 5
Slide 7: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated (Rs. In Lakhs) 6 Particulars Q1 FY22 Q1 FY21 Change (%) Total Income (I+II) 23,935 22,835 5 I. Total Revenue from Operations (A+B+C+D) 23,736 22,286 7 •API (A) 12,967 14,708 (12) •Formulations (B) 9,364 6,208 51 •Service Revenue & Product License Fees (C) 1,021
Slide 8: Abridged P&L Statement - Standalone
Abridged P&L Statement - Standalone (Rs. In Lakhs) 7 Particulars Q1 FY22 Q1 FY21 Change (%) Total Income (I+II) 25,012 21,928 14 I. Total Revenue from Operations (A+B+C+D) 24,033 21,664 11 •API (A) 12,967 14,708 (12) •Formulations (B) 10,274 5,619 83 •Service Revenue & Product License Fees (C) 526 7
Slide 9: Managing Director's Message
Managing Director’s Message 8 Commenting on Q1 FY’22 performance, Mr.Vishnukant Bhutada, Managing Director Shilpa Medicare Limited said “I am pleased to share we have witnessed a recovery in performance and delivered an encouraging set of results in Q1 even as the macro environment continues to rema
Slide 10: Discussion of Select Business Segments
Discussion of Select Business Segments 9
Slide 11: API - Highlights
API - Highlights 10 Segment wise sales (Rs. In Lakhs) Q4 FY21 Q1 FY21 Q1 FY22 - , 0% 877 , 7% 94 , 1% 414 , 3% 307 , 2% 3,671 , 3,244 , 27% 2,559 , 21% Oncology 21% Non-Oncology 8,674 , K-Product 9,443 , 8,789 , 2,828 , 57% 19% Others 71% 71% Rs. 13,422 Rs. 12,320 Rs. 15,161 o Increased offtake in J
Slide 12: Formulation - Highlights
Formulation - Highlights 11 Revenue Split (Rs. In Lakhs) 91 , Q1 FY22 385 , 4% Q4FY21 30 , 0% Q1FY21 52 , 1% 1% 923 , 17% 702 , 13% 2,140 , USA 4,522 , 198 , 4% 35% EUROPE 43% 5,419 , 3,968 , ROW 52% 64% INDIA 3,505 , 66% Rs. 10,417 Rs. 5,328 Rs. 6,190 o US business gaining traction again backed by
Slide 13: Investing in future Growth Businesses – New Launch
Investing in future Growth Businesses – New Launch 12 Launched fast dissolving oral films of Paracetamol brand name as Molshil® o Shilpa Medicare Ltd. recently announced the launch of Oral Thin Film Formulation, a Infant /pediatric dose of Paracetamol, under the Brand name Molshil® o The Company rec
Slide 14: Investing in future Growth Businesses – New Launch
Investing in future Growth Businesses – New Launch 13 In Insomnia & In Erectile Dysfunction In Seasonal Allergic Rhinitis, Asthma, Sleep Disorders ( Majorly through Retail Plan ) EIB, Perennial Allergic Rhinitis
Slide 15: Other Updates
Other Updates 14
Slide 16: Contribution towards combating to Covid-19 pandemic
Contribution towards combating to Covid-19 pandemic 15 Sputnik V vaccine update o Shilpa Biologicals Pvt Ltd, (SBPL) the wholly owned subsidiary of Shilpa Medicare Ltd. has entered in a 3-year definitive agreement with Dr. Reddy's Laboratories for the production-supply of SputnikV vaccine from its i
Slide 17: Contribution towards combating to Covid-19 pandemic
Contribution towards combating to Covid-19 pandemic 16 Received approval from DRDO for the manufacture and sale of 2-Deoxy-D-G1ucose (2DG) o Recently received an approval from the Defence Research & Development Organization (DRDO) for the manufacture and sale of 2-Deoxy- D-Glucose (2DG). o Shilpa Me
Slide 18: Current Status on USFDA Warning Letter
Current Status on USFDA Warning Letter 17 USFDA updates on formulation facility Completed gap assessment and ongoing remediation in place for the two major areas of concern cited by the USFDA •Handling of complaints and •Handling of laboratory investigations. A Master Compliance Action Plan Company
Slide 19: Patents Status as on June 30, 2021
Patents Status as on June 30, 2021 18 Patents Filings Granted Pending - API 205 40 165 - Formulation * 179 26 153 - Films Topical & Transdermal 59 6 53 - Biologicals 12 4 8 - Others 22 5 17 TOTAL 477 81 396 * Formulation numbers includes the Patents of FTF Pharma Pvt Ltd Ahmedabad, a wholly owned su
Slide 20: Formulation Product Pipeline as on June 30, 2021
Formulation Product Pipeline as on June 30, 2021 19 Regulatory Approved Filings Pending Submissions (Including Tentative) - US ANDA: SML 24 13 11 - US NDA: SML 03 01 02 - US ANDA: Customers 18 12 06 TOTAL (In US) 45 26 19 - EU Filing 24 17 07 - Row Filling 228 65 163 TOTAL (In EU & ROW) 252 82 170 G
Slide 21: Manufacturing Excellence
Manufacturing Excellence 20 Facility Location FacilityType Dharwad Biologicals Manufacturing plant & R & D Facility TDS & ODF Manufacturing Facility & Formulation Bengaluru Unit R&D Raichur Unit I API (Oncology – Non-Oncology) India India Raichur Unit II API (Oncology – Non-Oncology) and R & DAPI Ja
Slide 22: Ramping Up Capacities
Ramping Up Capacities Biologicals & Biosimilars ODF & Transdermal 21 API State-of-art mfg. facility to develop and manufacture novel 2 independent lines - single use lines (Expanded to 4000L tech-based products at Bengaluru facility for global market each) for production of MABS, vaccines and other
Slide 23: Way Forward
Way Forward 22
Slide 24: Way Forward…
Way Forward… 23 o Separate business under Shilpa Lifesciences Pvt. Ltd to provide focused approach resulting in better operating efficiency API o Greater impetus to specialty areas of CDMO, Peptides & Polymers o Completion of remedial measures towards USFDA import alert by Q2/Q3 of FY22 o Continue t
Slide 25: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. 24 Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated marke
Slide 26: Thank You
25 Thank You